Drug Trial Radar · NCT07530666
Study of the Safety and Efficacy of DS010 in Patients With Cancer Cachexia
Last checked: Nov 19, 2026Latest source record: Apr 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
58
Planned (sponsor's estimate)
Start
Apr 30, 2026
Primary completion
Oct 30, 2027
Study completion Apr 30, 2028
Sponsor
- Lead sponsor
- Dartsbio Pharmaceuticals Ltd.Industry
- Sponsor type
- Industry
- First posted
- Apr 15, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A study to evaluate the safety, tolerability, and preliminary efficacy of DS010 in patients with cancer and cachexia
Conditions
- Cancer
- Cachexia
Interventions
DS010 injectionDrug
Once every 3 weeks intravenously injection
DS010 injectionDrug
Once every 3 weeks intravenously injection
DS010 injectionDrug
Once every 3 weeks intravenously injection
DS010 injectionDrug
Once every 3 weeks intravenously injection
DS010 injectionDrug
Once every 3 weeks intravenously injection
DS010 injectionDrug
Once every 3 weeks intravenously injection
DS010 injectionDrug
Once every 3 weeks or once every 4 weeks intravenously injection
DS010 injectionDrug
Once every 3 weeks or once every 4 weeks intravenously injection
DS010 injectionDrug
Once every 3 weeks or once every 4 weeks intravenously injection
DS010 injectionDrug
Once every 3 weeks or once every 4 weeks intravenously injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase 1: Dose-limiting toxicity (DLT)Time frame: 21 days after the first dose
- Phase 1: Incidence of adverse events as assessed by CTCAE V6.0Time frame: Up to 20 weeks
- Phase 2: Change in body weight from baseline to Week 12Time frame: Baseline, Week 12
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.